Consistently, we found that GSCAR expression was higher in IDH1 wild-type (WT) gliomas than in IDH1 mutant (MUT) gliomas, and glioma patients with higher GSCAR expression exhibited worse clinical outcomes (Figure 1D-1E). This evidence concerns the gene IDH1 and central nervous system cancer.